# Oric Pharmaceuticals, Inc.: overview

ORIC · Nasdaq · CIK 1796280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oric.md) · [Financials](/companies/oric/financials.md) · [Filings](/companies/oric/filings.md) · [Insiders](/companies/oric/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.49)](/filings/0001193125-25-280234.md) | not reported | [(0.42)](/filings/0001193125-26-204047.md) | [(0.47)](/filings/0001193125-26-330631.md) | [(0.33)](/filings/0001193125-25-280234.md) | not reported | [(0.34)](/filings/0001193125-26-204047.md) | [(0.38)](/filings/0001193125-26-330631.md) |
| Free cash flow | $m | [(29.2) d](/filings/0001193125-25-280234.md) | [(28.3) d](/filings/0001193125-26-064005.md) | [(32.9)](/filings/0001193125-26-204047.md) | [(30.9) d](/filings/0001193125-26-330631.md) | [(25.1) d](/filings/0001193125-25-280234.md) | [(22.7) d](/filings/0001193125-26-064005.md) | [(32.4)](/filings/0001193125-26-204047.md) | [(32.0) d](/filings/0001193125-26-330631.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.07)](/filings/0000950170-23-008483.md) | [(2.25)](/filings/0000950170-24-029298.md) | [(1.96)](/filings/0000950170-25-022273.md) | [(1.83)](/filings/0001193125-26-064005.md) | [(1.47)](/filings/0001193125-26-064005.md) |
| Free cash flow | $m | [(60.5)](/filings/0000950170-23-008483.md) | [(77.2)](/filings/0000950170-24-029298.md) | [(86.5)](/filings/0000950170-25-022273.md) | [(114)](/filings/0001193125-26-064005.md) | [(112)](/filings/0001193125-26-064005.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/oric/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $77.6m | 7,162,637 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $73.9m | 6,823,973 |  | Added +839,421 |
| [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $72.9m | 6,728,116 |  | Unchanged |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $55.5m | 5,126,762 |  | Reduced −697,771 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $53.0m | 4,894,000 |  | Added +1,191,804 |
| [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $50.0m | 4,615,384 |  | Added +100,455 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $46.8m | 4,319,765 |  | Unchanged |
| [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $44.6m | 4,118,621 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $42.8m | 3,951,169 |  | Added +264,162 |
| [AIHC Capital Management Ltd](/funds/2103725.md) | 2026-06-30 | $41.5m | 3,828,460 |  | Added +1,368,909 |

## Recent filings

[All 416 filings](/companies/oric/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 08:00 ET | [8-K](/filings/0001193125-26-429465.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429465 |
| 2026-08-03 | 20:20 ET | [10-Q](/filings/0001193125-26-330631.md) | Quarterly report, period 2026-06-30 | 0001193125-26-330631 |
| 2026-08-03 | 20:10 ET | [8-K](/filings/0001193125-26-330568.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330568 |
| 2026-07-30 | 20:49 ET | [8-K](/filings/0001193125-26-326309.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-326309 |
| 2026-06-22 | 20:05 ET | [8-K](/filings/0001193125-26-277511.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277511 |
| 2026-05-04 | 20:20 ET | [10-Q](/filings/0001193125-26-204047.md) | Quarterly report, period 2026-03-31 | 0001193125-26-204047 |
| 2026-05-04 | 20:10 ET | [8-K](/filings/0001193125-26-203993.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-203993 |
| 2026-04-28 | 20:03 ET | [DEF 14A](/filings/0001193125-26-186911.md) | Proxy statement, period 2026-06-18 | 0001193125-26-186911 |
| 2026-03-31 | 20:16 ET | [8-K](/filings/0001193125-26-134618.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-134618 |
| 2026-02-23 | 22:06 ET | [8-K](/filings/0001193125-26-064291.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-064291 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-064005.md), filed Feb 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1796280
- Tickers: ORIC
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.